Search

Your search keyword '"van Vlijmen, Bas"' showing total 21 results
Start Over Author "van Vlijmen, Bas"
21 results on '"van Vlijmen, Bas"'

11. N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis

Author

Stunnenberg, Bas C, primary, Merkus, Esther C, additional, Raaphorst, Joost, additional, Saris, Christiaan GJ, additional, Groenewoud, Hans, additional, Statland, Jeffrey, additional, Weijma, Robyn, additional, van Vlijmen, Bas, additional, Griggs, Robert, additional, van Engelen, Baziel G M, additional, and van der Wilt, Gert Jan, additional

Published
2021
Full Text
View/download PDF

14. Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a Randomised Controlled Trial to evaluate the effect of monitoring patients' medication use combined with short message service (SMS) reminders

Author

Bouvy Marcel L, van Vlijmen Bas, Santen-Reestman Jacqueline, van Dijk Liset, Vervloet Marcia, and de Bakker Dinny H

Subjects
Public aspects of medicine, RA1-1270
Abstract

Abstract Background Innovative approaches are needed to support patients' adherence to drug therapy. The Real Time Medication Monitoring (RTMM) system offers real time monitoring of patients' medication use combined with short message service (SMS) reminders if patients forget to take their medication. This combination of monitoring and tailored reminders provides opportunities to improve adherence. This article describes the design of an intervention study aimed at evaluating the effect of RTMM on adherence to oral antidiabetics. Methods/Design Randomised Controlled Trial (RCT) with two intervention arms and one control arm involving diabetes type 2 patients with suboptimal levels of adherence to oral antidiabetics (less than 80% based on pharmacy refill data). Patients in the first intervention arm use RTMM including SMS reminders and a personal webpage where they can monitor their medication use. Patients in the second intervention arm use RTMM without SMS reminders or webpage access. Patients in the control arm are not exposed to any intervention. Patients are randomly assigned to one of the three arms. The intervention lasts for six months. Pharmacy refill data of all patients are available from 11 months before, until 11 months after the start of the intervention. Primary outcome measure is adherence to oral antidiabetics calculated from: 1) data collected with RTMM, as a percentage of medication taken as prescribed, and as percentage of medication taken within the correct time interval, 2) refill data, taking the number of days for which oral antidiabetics are dispensed during the study period divided by the total number of days of the study period. Differences in adherence between the intervention groups and control group are studied using refill data. Differences in adherence between the two intervention groups are studied using RTMM data. Discussion The intervention described in this article consists of providing RTMM to patients with suboptimal adherence levels. This system combines real time monitoring of medication use with SMS reminders if medication is forgotten. If RTMM proves to be effective, it can be considered for use in various patient populations to support patients with their medication use and improve their adherence. Trial registration Netherlands Trial Register NTR1882

Published
2011
Full Text
View/download PDF

15. The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

Author

Knapen, Lotte M, Koornstra, Rutger H T, Driessen, Johanna H M, van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R, Burger, David M, de Vries, Frank, van Erp, Nielka P, Knapen, Lotte M, Koornstra, Rutger H T, Driessen, Johanna H M, van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R, Burger, David M, de Vries, Frank, and van Erp, Nielka P

Abstract

BACKGROUND: The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is unknown.OBJECTIVES: To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reductions of vemurafenib and (2) simultaneous use of vemurafenib and ARAs.PATIENT AND METHODS: A retrospective cohort study of 112 first-line vemurafenib users for melanoma was conducted (March 2012-March 2016), using electronic patient records and pharmacy dispensing records of a Dutch academic hospital. Cox regression analysis was used to estimate the risk of progression with full-dose (n = 64) versus reduced-dose vemurafenib (n = 48) and with simultaneous use of vemurafenib and ARAs (n = 35) versus vemurafenib alone (n = 77). Analyses were adjusted for age and sex.RESULTS: In total, disease progression occurred in 55% of treated patients on vemurafenib, with a median progression-free survival of 6.0 (95% confidence interval [CI] 5.0-6.9) months. Compared to patients on vemurafenib alone, there was no increased risk of progression among patients requiring vemurafenib at a reduced dose or among patients receiving simultaneous therapy with vemurafenib and ARAs. In addition, there was no increased risk of progression among patients who used reduced-dose vemurafenib and ARAs versus those receiving full-dose vemurafenib as sole therapy. However, a tendency for progression was observed among patients who used full-dose vemurafenib and ARAs versus full-dose vemurafenib alone (adjusted hazard ratio [HRa] 2.37; 95% CI 0.97-5.76), which became statistically significant in a sensitivity analysis (HRa 4.56; 95% CI 1.51-13.75).CONCLUSIONS: There was no association between the use of vemurafenib in a reduced dose or the simultaneous use of vemurafenib and ARAs and the risk of progression. In addition, there was no association between the simultaneous use of vemurafenib in a reduced dose and ARAs and the ri

Published
2018

16. The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Knapen, Lotte M, Koornstra, Rutger H T, Driessen, Johanna H M, van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R, Burger, David M, de Vries, Frank, van Erp, Nielka P, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Knapen, Lotte M, Koornstra, Rutger H T, Driessen, Johanna H M, van Vlijmen, Bas, Croes, Sander, Schalkwijk, Stein, Colbers, Angela, Gerritsen, Winald R, Burger, David M, de Vries, Frank, and van Erp, Nielka P

Published
2018

18. Association of concomitant use of acid reducing agents in full-dose vemurafenib users with risk of progression in BRAF V600 mutation-positive unresectable or metastatic melanoma patients: A retrospective cohort study.

Author

Knapen, Lotte Marieke, primary, Koornstra, Rutger H.T., additional, Driessen, Johanna H.M., additional, Van Vlijmen, Bas, additional, Croes, Sander, additional, Schalkwijk, Stein J., additional, Colbers, Angela, additional, Gerritsen, Winald, additional, Burger, David, additional, de Vries, Frank, additional, and Van Erp, Nielka P., additional

Published
2017
Full Text
View/download PDF

21. Preface

Author

Ponse, Alban, primary, Verhoef, Chris, additional, and van Vlijmen, Bas, additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results